新辅助性胃评分:新辅助性化疗反应如何影响整体存活率和辅助性益处
Chase J Wehrle1, Caleb N Seavey2, Jenny Chang2
1Department of General Surgery, Cleveland Clinic Foundation, Cleveland, OH, USA. wehrlec@ccf.org.
Annals of surgical oncology
|September 2, 2023
概括
适应直肠癌的新辅助性胃 (NAG) 评分有效预测晚期胃癌患者的生存率. 它还有助于确定辅助疗法是否有利于高NAG分数的患者.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 癌症预后 癌症预后
背景情况:
- 新辅助性直肠 (NAR) 评分预测了直肠癌的生存率.
- 它对胃腺癌的适用性需要研究.
研究的目的:
- 评估局部晚期胃腺癌的NAR得分的重新使用.
- 评估新辅助性胃 (NAG) 评分能够预测5年整体存活 (OS) 的能力.
- 确定NAG评分是否可以指导辅助治疗决策.
主要方法:
- 从国家癌症数据库中获取胃腺癌患者的数据.
- 计算的新辅助性胃 (NAG) 评分,并将患者分为低,中,高组.
- 使用倾向匹配进行1:1:1的整体生存 (OS) 和辅助治疗分析的比较.
主要成果:
- 确定了2970名患者,NAG分数分布:低 (13.3%),中等 (25.5%) 和高 (61.2%).
- 倾向匹配分析显示,五年后的生存状况有显著差异:低NAG (82%),中等NAG (73%) 和高NAG (39%) (p < 0.001).
- NAG评分预测了辅助治疗的益处,只有高NAG患者的生存状况有所改善 (39%对29%;p=0.024).
结论:
- 新辅助性胃 (NAG) 评分可以从新辅助性直肠 (NAR) 评分重新使用.
- 该NAG评分是一个有价值的预后工具,用于预测胃腺癌的5年OS.
- 在胃癌治疗中,NAG评分可以指导使用辅助疗法的决定.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
相关概念视频
01:21Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
198
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
198
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K